Commentary Open Access
Volume 2 | Issue 5 | DOI: https://doi.org/10.33696/immunology.2.053
Sofosbuvir/Velpatasvir/Voxilaprevir for Previously DAA-treated Patients with Chronic Hepatitis C?
Llaneras J1,2,*, Riveiro-Barciela M2,3, Esteban R2,3, Buti M2,3
- 1Emergency Room Department, Vall d’Hebron University Hospital, Barcelona, Department of Medicine of UAB (Universitat Autònoma de Barcelona), Spain
- 2Liver Unit, Internal Medicine Department, Vall d’Hebron University Hospital, Barcelona, Spain
- 3Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto Carlos III, Barcelona,Spain
Corresponding Author
Llaneras J, jllanera@vhebron.net
Received Date: July 21, 2020
Accepted Date: August 26, 2020
Citation:
Llaneras J, Riveiro-Barciela M, Esteban R, Buti M. Sofosbuvir/Velpatasvir/Voxilaprevir for Previously DAA-treated Patients with Chronic Hepatitis C? J Cell Immunol. 2020; 2(5): 259-264.
Copyright: © 2020 Llaneras J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.